HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) shares shot up 4.3% during mid-day trading on Wednesday . The company traded as high as $18.43 and last traded at $18.43. 142,091 shares changed hands during trading, a decline of 49% from the average session volume of 280,462 shares. The stock had previously closed at $17.67.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on shares of HUTCHMED in a research report on Wednesday, October 12th. They set a “hold” rating for the company.
HUTCHMED Price Performance
The business’s fifty day simple moving average is $14.39 and its two-hundred day simple moving average is $12.32.
Institutional Investors Weigh In On HUTCHMED
HUTCHMED Company Profile
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.